GlaxoSmithKline provided information about its second-quarter financials this week. The attention focused on plans to kill more than 30 preclinical and clinical programs and allocate 80 percent of its research-and-development budget to respiratory and HIV/infectious diseases. But a closer look at new CEO Emma Walmsley’s plans point to big changes in the company’s manufacturing network as well.
Boston Scientific called a single pacemaker-related death for its S-ICD implant a “fluke” that was the result of radiation corruption that negatively impacted the device’s memory.
Republican and Democratic lawmakers discussed ways to prevent drugmakers from using rules developed to safeguard patients to instead block the sale of cheaper medicines.
Amgen Inc. said the U.S. FDA granted priority review to the company’s request to add important heart safety data to the label of its expensive injectable cholesterol drug Repatha.
U.S. Democratic Senator Claire McCaskill expanded an investigation into the causes of the opioid crisis plaguing the country, seeking information from four more drugmakers and three drug distributors.
Bristol-Myers Squibb shares fell as a failed cancer-drug trial at AstraZeneca could have negative implications for its similar immunotherapy treatment regimen.
Scientists in Chile have discovered molecules in two species of Antarctic flowers that protect the plants from solar radiation and could potentially be used in products such as sunscreen for humans and protection for vulnerable crops.
There is a ray of sunshine for beleaguered Tesaro as Japanese pharma giant Takeda Pharmaceutical struck a deal worth up to $340 million for Asian development and marketing rights for recently approved PARP inhibitor Zejula (niraparib).
Astellas Pharma announced that the company is wrapping up its research operations with Santa Monica, Calif.-based Agenus.
Alexion Redefines R&D Strategy, Discontinues Programs and Kills Deals With Moderna, Blueprint and Arbutus Biopharma
While reporting strong earnings, New Haven, Conn.-based Alexion Pharmaceuticals also indicated the company plans to retool its research-and-development strategy.